BioPharma Dive January 6, 2025
Ben Fidler, Delilah Alvarado and Jacob Bell

Every presidential election brings change to the Food and Drug Administration. This time around, the upheaval could be particularly jarring.

The nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, which oversees the FDA and other health agencies, brings new uncertainty to the regulator’s future. Even with Marty Makary — viewed as a more traditional pick for FDA Commissioner — possibly leading the regulator, Kennedy’s presence would have broad implications for the agency and its workforce. Three high-ranking officials have already...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies
Related Articles:
FDA offers new draft guidance to developers of AI-enabled medical devices
Chevron’s Fall And Its Impact On Medical AI
FDA closes 2024 with string of early alerts on device safety risks
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
Few medical devices are designed for children. An FDA-Children’s National collaboration aims to change that.

Share This Article